CDCP1 and neoplasm: Its potential as a target is supported by reports that five anti-CDCP1 antibodies, or antibody fragments, have demonstrated the ability, in in vivo models, to inhibit tumor growth or metastasis [10-13], with one of these antibodies successfully tested in a breast cancer tumor regression model [12].